Darpa awards AnaptysBio up to $1.5 million to generate high affinity thermally stable antibodies

Proprietary somatic hypermutation (SHM) platform to generate novel antibodies for detecting toxic substances, bioterrorist threats

SAN DIEGO, CA - July 12, 2010

AnaptysBio, Inc., a privately-held therapeutic antibody platform and product company, today announced it has been awarded a contract by the Defense Advanced Research Projects Agency (DARPA), to use its proprietary somatic hypermutation (SHM) technology platform to generate novel high affinity thermally stable antibodies that could be used by the military in antibody-based biosensors, including those that can detect bioterrorist threats.

Click here to read AnaptysBio's news release.